Literature DB >> 6805075

Role of calcium in trypanocidal drug action.

A B Clarkson, B O Amole.   

Abstract

The synergistic effect of serum on the drug combination of salicylhydroxamic acid plus glycerol, which is active against Trypanosoma brucei, is due to diffusible calcium ions. The synergistic activity can be removed by dialysis of the serum or by addition of calcium chelating agents. A buffer containing calcium can mimic the synergistic activity of serum. This finding may have important implications in the clinical management of African trypanosomiasis in humans. Calcium also has a synergistic effect on melarsoprol, the only drug available for treating sleeping sickness patients with central nervous system involvement, and the concentration of calcium has been reported to be depressed inthe serum of experimentally infected animals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6805075     DOI: 10.1126/science.6805075

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  4 in total

1.  Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense.

Authors:  C J Bacchi; H C Nathan; T Livingston; G Valladares; M Saric; P D Sayer; A R Njogu; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Calcium entry in Trypanosoma brucei is regulated by phospholipase A2 and arachidonic acid.

Authors:  J Eintracht; R Maathai; A Mellors; L Ruben
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

3.  Identification of intracellular and plasma membrane calcium channel homologues in pathogenic parasites.

Authors:  David L Prole; Colin W Taylor
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

Review 4.  Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target Against Trypanosoma cruzi.

Authors:  Gustavo Benaim; Alberto E Paniz-Mondolfi; Emilia Mia Sordillo; Nathalia Martinez-Sotillo
Journal:  Front Cell Infect Microbiol       Date:  2020-02-14       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.